MONTVALE, N.J., Oct. 8, 2008 (GLOBE NEWSWIRE) -- Datascope Corp. (Nasdaq:DSCP) announced today that it will sponsor a 300-patient, randomized clinical trial in high-risk acute myocardial infarction (MI) patients who are not in cardiogenic shock to show the efficacy of intra-aortic balloon counterpulsation (IAB) in reducing infarct size. Patients enrolled in the CRISP* AMI trial will be randomized equally to usual care versus usual care plus intra-aortic balloon counterpulsation (IABC) therapy prior to percutaneous coronary intervention. The primary efficacy endpoint will be a 25% reduction in infarct size due to IABC utilization. The successful completion of this trial represents a worldwide opportunity of more than 200,000 patients, or $200 million per year.
